Working… Menu

GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE™) for High Risk Heme Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03214666
Recruitment Status : Recruiting
First Posted : July 11, 2017
Last Update Posted : June 11, 2020
Information provided by (Responsible Party):
GT Biopharma, Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 1, 2024
Estimated Study Completion Date : August 1, 2025